Riccardo Capocaccia

Dr. Riccardo Capocaccia


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
LBLaura Botta
Laura Botta
GGGemma Gatta
Gemma Gatta
ATAnnalisa Trama
Annalisa Trama
ABAlice Bernasconi
Alice Bernasconi
ESElad Sharon
Elad Sharon
TGthe RARECAREnet working group
the RARECAREnet working group
Geographical variability of cancer burden was almost exclusively estimated for common cancers. Since rare cancers (RC) have become an area of priority for basic and clinical research and public health organizations, this paper provides, using a common methodology, a detailed comparison of incidence and survival for RC in the US and Europe. We estimated incidence and net survival of 199 malignant RC from data of 2 580 000 patients collected by 18 US‐SEER and 94 European registries, diagnosed within the most recent common period 2000‐2007. RC were defined according to the criterion of crude annual incidence rates 65+ years of age. Use of standardized methods evidenced that incidence and survival rate of majority of RC were higher in the United States compared to Europe. Possible reasons for such differences, requiring further studies, include distribution of risk factors, ability to diagnose RC, different registration practices, and use of updated International Classification of Diseases for Oncology.

9 July 2024 in European Journal of Cancer
Verified
Journal Article
Closed access
LBLaura Botta
Laura Botta
RCRiccardo Capocaccia
Riccardo Capocaccia
ABAlice Bernasconi
Alice Bernasconi
SRSilvia Rossi
Silvia Rossi
JGJaume Galceran
Jaume Galceran
VJValerie Jooste
Valerie Jooste

29 October 2021 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
DSDiego Salmerón
Diego Salmerón
LBLaura Botta
Laura Botta
JMJosé Miguel Martínez-Martínez
José Miguel Martínez-Martínez
ATAnnalisa Trama
Annalisa Trama
Gemma GattaGemma Gatta
Gemma Gatta
FGfor the Information Network on Rare Cancers (RARECARENet) Working Group
for the Information Network on Rare Cancers (RARECARENet) Working Group
Estimating incidence of rare cancers is challenging for exceptionally rare entities and in small populations. In a previous study, investigators in the Information Network on Rare Cancers (RARECARENet) provided Bayesian estimates of expected numbers of rare cancers and 95% credible intervals for 27 European countries, using data collected by population-based cancer registries. In that study, slightly different results were found by implementing a Poisson model in integrated nested Laplace approximation/WinBUGS platforms. In this study, we assessed the performance of a Poisson modeling approach for estimating rare cancer incidence rates, oscillating around an overall European average and using small-count data in different scenarios/computational platforms. First, we compared the performance of frequentist, empirical Bayes, and Bayesian approaches for providing 95% confidence/credible intervals for the expected rates in each country. Second, we carried out an empirical study using 190 rare cancers to assess different lower/upper bounds of a uniform prior distribution for the standard deviation of the random effects. For obtaining a reliable measure of variability for country-specific incidence rates, our results suggest the suitability of using 1 as the lower bound for that prior distribution and selecting the random-effects model through an averaged indicator derived from 2 Bayesian model selection criteria: the deviance information criterion and the Watanabe-Akaike information criterion.

14 September 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
AMAngela B. Mariotto
Angela B. Mariotto
LBLaura Botta
Laura Botta
ABAlice Bernasconi
Alice Bernasconi
ZZZhaohui Zou
Zhaohui Zou
Gemma GattaGemma Gatta
Gemma Gatta
RCRiccardo Capocaccia
Riccardo Capocaccia
Background: To estimate risk of recurrence for women diagnosed with nonmetastatic breast cancer considering the risks of other causes mortality. Methods: We extend a method based on the diagnosis–metastasis–death pathway to include risks of other causes mortality. We estimate three probabilities as cumulative incidence of: (i) being alive and recurrence-free, (ii) death for other causes before a recurrence, and (iii) recurrence. We apply the method to female breast cancer relative survival from the Surveillance, Epidemiology, and End Results Program registries (2000–2018) data. Results: The cumulative incidence of recurrence shows a higher increase with more advanced cancer stage and is less influenced by age at diagnosis. At 5 years from diagnosis, the cumulative incidence of recurrence is less than 3% for those diagnosed with stage I, 10% to 13% for those diagnosed with stage II, and 37% to 47% for those diagnosed with stage III breast cancer. The estimates of recurrence considering versus ignoring the risks of dying from other causes were generally consistent, except for older women with more advanced stage, and longer time since diagnosis. In these groups, the net probability of recurrence, excluding the risks of dying from other causes, were overestimated. Conclusions: For patients with cancer who are older or long-term survivors, it is important to include the risks of other cause mortality as the crude cumulative incidence of recurrence is a more appropriate measure. Impact: These estimates are important in clinical decision making, as higher competing mortality may preclude the benefits of aggressive treatments.

5 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FDFabio Didonè
Fabio Didonè
ATAndrea Tittarelli
Andrea Tittarelli
CTClaudio Tresoldi
Claudio Tresoldi
PCPaolo Contiero
Paolo Contiero
RCRiccardo Capocaccia
Riccardo Capocaccia
BGBENCHISTA-Ita Working Group
BENCHISTA-Ita Working Group
Background: Childhood cancers (CC) are rare and treatable; however, survival rates vary across Europe, with poorer outcomes in Eastern countries. Stage at diagnosis is one of the major prognostic factors. The BENCHISTA-Ita project aims to promote the use of the Toronto Guidelines by population-based cancer registries (PBCR) to standardize stage at diagnosis data collection. In Italy, regional cancer registries ensure data quality, while national clinical registries centralize pediatric cancer data. The aim of the study is to promote the linkage between PBCRs and national clinical registries to enhance data completeness. This study presents the results of linking BENCHISTA-Ita neuroblastoma cases with the Italian Neuroblastoma Registry (RINB) as a pilot study. Methods: The linkage process involved probabilistic matching using R software, considering variables such as sex, year of birth, and residence at diagnosis. The study included 294 neuroblastoma cases from BENCHISTA-Ita and 578 from RINB, diagnosed between 2013 and 2017. Results: Results showed that 272 of 294 BENCHISTA-Ita cases matched with RINB cases, improving the completeness of clinical variables such as stage at diagnosis, N-Myc amplification, and relapse/progression. The linkage increased the completeness of clinical variables in PBCR, such as stage at diagnosis from 81% to 99%, N-Myc from 47% to 86%, and relapse/progression from 68% to 98%. Additionally, the linkage improved RINB’s follow-up completeness from 59% to 97% and added new cases in both PBCR and RINB. Conclusions: This linkage demonstrates the potential to enrich both databases, improving data quality and harmonization of cancer indicators. The study highlights the importance of collaboration between PBCRs and clinical registries to ensure comprehensive data collection and enhance more informative population-based studies. Future efforts will focus on expanding the linkage to other national clinical registries.

19 April 2025 in European Journal of Cancer
Verified
Journal Article
Open access
LBLaura Botta
Laura Botta
RCRiccardo Capocaccia
Riccardo Capocaccia
CVClaudia Vener
Claudia Vener
ABAlice Bernasconi
Alice Bernasconi
ATAnnalisa Trama
Annalisa Trama
VJValerie Jooste
Valerie Jooste
Adolescents and young adults (AYAs), aged 15-39, face unique challenges as cancer survivors, including long-term health issues treatment. This study applies a novel approach to estimate the relative risk (RR) of mortality from non-cancer causes in AYA cancer patients compared to the general population and the cure fraction (CF) for AYA patients. Conventional and new mixture cure models with various parametric survival functions were applied to the most common AYA cancers. EUROCARE-6 cases diagnosed between 1998 and 2002, with follow-up to 2014, were selected. Qualitative and quantitative criteria were used to select the optimal model. CFs and RRs were estimated by cancer type, age group, and sex. RRs> 1 were found in both sexes for leukaemia, chronic myeloid leukaemia, lymphoma, central nervous system (CNS) tumours, and skin melanoma, and for testicular germ cell, breast and cervix cancers, with RR generally higher in younger patients and decreasing with age. For acute myeloid leukaemia, colorectal cancer, bone sarcoma for both sexes and soft tissue sarcoma, acute lymphoblastic leukaemia (ALL), and ovary germ cell in females, there was no indication for extra risk. Higher CFs were found in adolescents compared to older AYAs (30-39 years), especially for ALL, CNS tumours in males, and colorectal cancer in females. Further studies are needed to understand why RRs are elevated in AYA patients, to investigate comorbidities and side effects of treatment. Accurate estimation of cancer mortality and CF is vital for resource allocation, tailored follow-up care, and imporving patient quality of life.